MX2024003967A - Resmetirom para reducir el volumen del higado. - Google Patents
Resmetirom para reducir el volumen del higado.Info
- Publication number
- MX2024003967A MX2024003967A MX2024003967A MX2024003967A MX2024003967A MX 2024003967 A MX2024003967 A MX 2024003967A MX 2024003967 A MX2024003967 A MX 2024003967A MX 2024003967 A MX2024003967 A MX 2024003967A MX 2024003967 A MX2024003967 A MX 2024003967A
- Authority
- MX
- Mexico
- Prior art keywords
- resmetirom
- prodrug
- reducing liver
- liver volume
- cirrhotic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente divulgación describe un método para reducir el volumen hepático en un sujeto cirrótico o no cirrótico, comprendiendo el método administrar resmetirom, un profármaco del mismo, o una sal farmacéuticamente aceptable del resmetirom o el profármaco de resmetirom. La presente divulgación también describe un método para tratar NASH en un sujeto cirrótico que lo necesita, comprendiendo el método administrar al sujeto resmetirom, un profármaco del mismo, o una sal farmacéuticamente aceptable del resmetirom o el profármaco de resmetirom.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163248634P | 2021-09-27 | 2021-09-27 | |
| PCT/US2022/044826 WO2023049491A1 (en) | 2021-09-27 | 2022-09-27 | Resmetirom for reducing liver volume |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024003967A true MX2024003967A (es) | 2024-06-03 |
Family
ID=83900064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024003967A MX2024003967A (es) | 2021-09-27 | 2022-09-27 | Resmetirom para reducir el volumen del higado. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240408102A1 (es) |
| EP (2) | EP4578499A3 (es) |
| JP (1) | JP2024536126A (es) |
| KR (1) | KR20240073926A (es) |
| CN (1) | CN118251221A (es) |
| AR (1) | AR127165A1 (es) |
| AU (1) | AU2022348966A1 (es) |
| CA (1) | CA3233319A1 (es) |
| CL (1) | CL2024000886A1 (es) |
| IL (1) | IL311670A (es) |
| MX (1) | MX2024003967A (es) |
| TW (1) | TW202337470A (es) |
| WO (1) | WO2023049491A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024251233A1 (zh) * | 2023-06-08 | 2024-12-12 | 成都微芯药业有限公司 | PPAR全激动剂联合THR-β激动剂在抗代谢相关疾病中的用途 |
| US20240423992A1 (en) * | 2023-06-22 | 2024-12-26 | Madrigal Pharmaceuticals, Inc. | Biomarkers for treating liver disorders with thr-b agonists and related uses |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY170520A (en) | 2012-09-17 | 2019-08-08 | Madrigal Pharmaceuticals Inc | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
-
2022
- 2022-09-27 AU AU2022348966A patent/AU2022348966A1/en active Pending
- 2022-09-27 KR KR1020247013928A patent/KR20240073926A/ko active Pending
- 2022-09-27 CA CA3233319A patent/CA3233319A1/en active Pending
- 2022-09-27 AR ARP220102600A patent/AR127165A1/es unknown
- 2022-09-27 IL IL311670A patent/IL311670A/en unknown
- 2022-09-27 TW TW111136510A patent/TW202337470A/zh unknown
- 2022-09-27 CN CN202280075697.1A patent/CN118251221A/zh active Pending
- 2022-09-27 MX MX2024003967A patent/MX2024003967A/es unknown
- 2022-09-27 EP EP24212126.7A patent/EP4578499A3/en active Pending
- 2022-09-27 WO PCT/US2022/044826 patent/WO2023049491A1/en not_active Ceased
- 2022-09-27 US US18/695,572 patent/US20240408102A1/en active Pending
- 2022-09-27 JP JP2024519112A patent/JP2024536126A/ja active Pending
- 2022-09-27 EP EP22793025.2A patent/EP4408428A1/en not_active Withdrawn
-
2024
- 2024-03-26 CL CL2024000886A patent/CL2024000886A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4408428A1 (en) | 2024-08-07 |
| KR20240073926A (ko) | 2024-05-27 |
| CA3233319A1 (en) | 2023-03-30 |
| IL311670A (en) | 2024-05-01 |
| US20240408102A1 (en) | 2024-12-12 |
| EP4578499A2 (en) | 2025-07-02 |
| AU2022348966A1 (en) | 2024-04-11 |
| JP2024536126A (ja) | 2024-10-04 |
| WO2023049491A1 (en) | 2023-03-30 |
| AR127165A1 (es) | 2023-12-27 |
| CN118251221A (zh) | 2024-06-25 |
| CL2024000886A1 (es) | 2024-08-30 |
| EP4578499A3 (en) | 2025-09-17 |
| TW202337470A (zh) | 2023-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202204929B (en) | Rimegepant for cgrp related disorders | |
| MX2022001863A (es) | Metodos para tratar los tumores del estroma gastrointestinal. | |
| WO2020033838A3 (en) | Treatment of egfr-mutant cancer | |
| MY201629A (en) | Benzopyrazole compounds and analogues thereof | |
| MX2021005075A (es) | Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion. | |
| PH12021550958A1 (en) | Trifluoromethyl-substituted sulfonamide as bcl-2-selective inhibitor | |
| MX2024003967A (es) | Resmetirom para reducir el volumen del higado. | |
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| MX2023001071A (es) | Tratamiento de la migraña. | |
| MX2021002305A (es) | Tratamiento de trastornos del higado. | |
| MX2024003952A (es) | Combinación que comprende atogepant para tratar la migraña. | |
| JOP20220104A1 (ar) | نظام تجريع لعوامل مضادة لـ dll3 | |
| MX2021008010A (es) | Composiciones y métodos para tratar las enfermedades del hígado graso no alcohólico (nafld). | |
| MX2020007971A (es) | Composiciones y metodos para tratar edema pulmonar o inflamacion pulmonar. | |
| PH12021550713A1 (en) | Medicament for the treatment of chronic cough | |
| MX2021001435A (es) | Tripeptidos y tratamiento de trastornos metabolicos, cardiovasculares e inflamatorios. | |
| MX2023013225A (es) | Inhibidores de la cinasa 4 similar a polo. | |
| ZA202209104B (en) | Intradialytic use of sodium thiosulfate | |
| MY203645A (en) | Ret inhibitor for use in treating cancer having a ret alteration | |
| MX2023013715A (es) | Regímenes de dosis de ecubectedina. | |
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| EA035519B9 (ru) | 1,3,4-тиадиазольные соединения и их применение в лечении рака | |
| MY197685A (en) | Use of a pharmaceutical composition in the manufacture of a medicament for treating a malignant pleural effusions | |
| MX2021001832A (es) | Conjugados para su uso en metodos de tratamiento del cancer. |